Journal of cardiac failure · 2025
Amiodarone Association With Severe Primary Graft Dysfunction and Vasoactive Inotropic Score After Heart Transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dorsey Natalie S, Biscopink Alec E, Houston Brian A, Atkins Jessica, Kilic Arman, Gregoski Mathew, Tedford Ryan J, Griffin Jan M
Аннотация
BACKGROUND: The impact of amiodarone on severe primary graft dysfunction (PGD) and vasoactive inotropic scores (VISs) following heart transplantation (HT) is unclear.
METHODS AND RESULTS: We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.
CONCLUSIONS: Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.
METHODS AND RESULTS: We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.
CONCLUSIONS: Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.